Health sciences company PreveCeutical Medical (CSE: PREV)
(OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed an
agreement with Asterion Cannabis Inc. to acquire a worldwide license to use,
manufacture, distribute and sell three Health Canada approved natural health
products. Per the terms of the licensing agreement, Asterion has granted
PreveCeutical a non-exclusive license to use Asterion’s intellectual property
to make or have made, use, distribute, sell, offer to sell and promote the
products in exchange for a royalty fee payable to Asterion equaling 20% of the
gross sales. The licensing agreement’s initial term is five years and is
renewable for five consecutive one-year terms. In addition, PreveCeutical also
announced its entrance into an agreement with Monster Media, LLC for investor
relations (“IR”) services. Per the terms of the IR agreement, Monster Media
will provide investor relations and marketing services to the company for a
period of three months, at which time PreveCeutical has the option to renew for
subsequent three-month terms. Among other marketing tools, Monster Media will
host and display advertorial content supplied by the company. PreveCeutical has
paid Monster Media a one-time marketing fee of $50,000 and will pay a monthly
hosting fee of $2,000.
To view the full press release, visit http://ibn.fm/tzxqi
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops
innovative options for preventive and curative therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive
health sciences and currently has five research and development programs,
including: dual gene therapy for curative and prevention therapies for diabetes
and obesity; the Program; Nature Identical™ peptides for treatment of various
ailments; non-addictive analgesic peptides as a replacement to the highly
addictive analgesics such as morphine, fentanyl and oxycodone; and a
therapeutic product for treating athletes who suffer from concussions (mild
traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster.
CELLB9® is an oral solution containing polarized and potentiated essential
minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion
venom. This product is available on the company’s website. For more
information, visit the company’s website at www.PreveCeutical.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment